FDA panel meetings in September:
This article was originally published in Clinica
On September 20th the US FDA's anaesthesiology and respiratory therapy devices panel will consider a guidance document for premarket notification submissions for continuous positive airway pressure devices for treatment of obstructive sleep apnoea. The panel will also discuss the exemption of specific anaesthesiology and respiratory therapy devices from 510(k) review. At its meeting on September 25th, the neurological devices panel will vote on a PMA for an implantable upper extremity functional neuroprosthetic device.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.